Actinium Pharmaceuticals Inc (ATNM)

[Paulness]

NEWS -- Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting

• Iomab-B and multiple abstracts selected for inclusion at leading medical conference focused on bone marrow transplant and cellular therapy

NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that a presentation of data from the pivotal Phase 3 SIERRA trial of Iomab-B has been selected as one of four late breaking oral presentations at the 2019 TCT or Transplantation & Cellular Therapy Meetings™ of ASBMT and CIBMTR, which is being held February 20 – 24 in Houston, Texas. In addition, three abstracts related to Actinium's targeted conditioning pipeline have been accepted for poster presentations.

Sandesh Seth, Chairman and CEO of Actinium, said, "TCT is the ideal venue for us to present data and highlight our targeted conditioning programs as it is the pre-eminent medical meeting focused on bone marrow transplant and cellular therapy. We are excited to have multiple opportunities to highlight clinical data for Iomab-as well as update on Iomab-ACT, our newest program focused on lymphodepletion prior to CAR-T. In addition, we are involved with several events, educational and otherwise, that will enable us to educate a broad audience of investigators, researchers and potential partners about the SIERRA trial and our highly differentiated multi-disease, multi-target targeted conditioning pipeline. We expect this meeting to be a highly productive and consequential one for our company."

To see full PR with schedules view the original content here: http://www.prnewswire.com/news-releases/iomab-b-one-of-four-late-breaking-oral-presentations-to-be-presented-at-the-2019-transplantation--cellular-therapy-annual-meeting-300793634.html